In general, the presence of B cells and tumor-associated TLS correlates with a better prognosis in multiple cancer types including CRC [24,[37], [38], [39]], and predicts responsiveness to immune checkpoint inhibitors such as anti-PD1 or anti-CTLA4 [[40], [41], [42], [43]]. Here, CTLA4 is linked to neoplasm.